These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25810246)

  • 1. The Signature Program: Bringing the Protocol to the Patient.
    Kang BP; Slosberg E; Snodgrass S; Lebedinsky C; Berry DA; Corless CL; Stein S; Salvado A
    Clin Pharmacol Ther; 2015 Aug; 98(2):124-6. PubMed ID: 25810246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multigene Panel Testing in Oncology Practice: How Should We Respond?
    Kurian AW; Ford JM
    JAMA Oncol; 2015 Jun; 1(3):277-8. PubMed ID: 26181167
    [No Abstract]   [Full Text] [Related]  

  • 3. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

  • 4. Brave-ish New World--What's Needed to Make Precision Oncology a Practical Reality.
    MacConaill LE; Lindeman NI; Rollins BJ
    JAMA Oncol; 2015 Oct; 1(7):879-80. PubMed ID: 26181886
    [No Abstract]   [Full Text] [Related]  

  • 5. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maurie Markman on the Groundbreaking TAPUR Trial.
    Markman M
    Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
    [No Abstract]   [Full Text] [Related]  

  • 7. Personalized oncology in interventional radiology.
    Abi-Jaoudeh N; Duffy AG; Greten TF; Kohn EC; Clark TW; Wood BJ
    J Vasc Interv Radiol; 2013 Aug; 24(8):1083-92; quiz 1093. PubMed ID: 23885909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision oncology: where next?
    Gore M; Larkin J
    Lancet Oncol; 2015 Dec; 16(16):1593-5. PubMed ID: 26678189
    [No Abstract]   [Full Text] [Related]  

  • 9. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
    Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
    Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 12. Utilization of Genomics and Functional Genomics to Inform Clinical Decisions in IR.
    Schachtschneider KM; Gaba RC
    J Vasc Interv Radiol; 2018 Aug; 29(8):1117-1121. PubMed ID: 30055782
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cancer: three eras of personalized medicine].
    Jordan B
    Med Sci (Paris); 2017 Oct; 33(10):905-908. PubMed ID: 28994388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology.
    Patel SP; Schwaederle M; Daniels GA; Fanta PT; Schwab RB; Shimabukuro KA; Kesari S; Piccioni DE; Bazhenova LA; Helsten TL; Lippman SM; Parker BA; Kurzrock R
    Oncotarget; 2015 Oct; 6(32):32602-9. PubMed ID: 26418953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
    Molloy MP; Engel A
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision cancer medicine: the future is now, only better.
    Tsimberidou AM; Eggermont AM; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived cell models as preclinical tools for genome-directed targeted therapy.
    Lee JY; Kim SY; Park C; Kim NK; Jang J; Park K; Yi JH; Hong M; Ahn T; Rath O; Schueler J; Kim ST; Do IG; Lee S; Park SH; Ji YI; Kim D; Park JO; Park YS; Kang WK; Kim KM; Park WY; Lim HY; Lee J
    Oncotarget; 2015 Sep; 6(28):25619-30. PubMed ID: 26296973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
    Horlings HM; Shah SP; Huntsman DG
    JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer molecular markers: A guide to cancer detection and management.
    Nair M; Sandhu SS; Sharma AK
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):39-55. PubMed ID: 29428478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.